Vericel Co. (NASDAQ:VCEL) Given Average Recommendation of “Hold” by Brokerages

Shares of Vericel Co. (NASDAQ:VCELGet Rating) have received a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $36.75.

VCEL has been the subject of a number of research reports. StockNews.com initiated coverage on Vericel in a research report on Wednesday, October 12th. They issued a “sell” rating for the company. BTIG Research downgraded Vericel from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 9th. Truist Financial raised their price objective on Vericel from $22.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, December 20th. Stephens initiated coverage on Vericel in a research report on Thursday, October 13th. They issued an “overweight” rating and a $40.00 price objective for the company. Finally, HC Wainwright raised their target price on Vericel from $35.00 to $37.00 and gave the stock a “buy” rating in a research report on Tuesday, January 3rd.

Insider Buying and Selling

In related news, CEO Dominick Colangelo sold 39,938 shares of the firm’s stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $27.13, for a total transaction of $1,083,517.94. Following the completion of the transaction, the chief executive officer now owns 157,066 shares in the company, valued at approximately $4,261,200.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vericel

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its holdings in Vericel by 1.3% during the 3rd quarter. BlackRock Inc. now owns 7,180,238 shares of the biotechnology company’s stock valued at $166,583,000 after purchasing an additional 92,494 shares in the last quarter. State Street Corp increased its holdings in Vericel by 15.6% during the 2nd quarter. State Street Corp now owns 3,400,735 shares of the biotechnology company’s stock valued at $85,631,000 after purchasing an additional 458,219 shares in the last quarter. Vanguard Group Inc. increased its holdings in Vericel by 2.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,234,095 shares of the biotechnology company’s stock valued at $75,031,000 after purchasing an additional 88,923 shares in the last quarter. Fred Alger Management LLC increased its holdings in Vericel by 0.5% during the 3rd quarter. Fred Alger Management LLC now owns 1,944,578 shares of the biotechnology company’s stock valued at $45,114,000 after purchasing an additional 10,557 shares in the last quarter. Finally, Macquarie Group Ltd. increased its holdings in Vericel by 1.3% during the 2nd quarter. Macquarie Group Ltd. now owns 1,543,190 shares of the biotechnology company’s stock valued at $38,858,000 after purchasing an additional 19,685 shares in the last quarter.

Vericel Stock Up 2.0 %

Shares of NASDAQ:VCEL opened at $28.98 on Friday. The business has a 50 day moving average price of $24.34 and a 200 day moving average price of $25.65. Vericel has a twelve month low of $17.30 and a twelve month high of $43.97. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -74.31 and a beta of 1.83.

Vericel (NASDAQ:VCELGet Rating) last announced its quarterly earnings data on Wednesday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Vericel had a negative return on equity of 10.41% and a negative net margin of 11.36%. The firm had revenue of $38.55 million during the quarter, compared to the consensus estimate of $40.02 million. Analysts anticipate that Vericel will post -0.45 EPS for the current year.

Vericel Company Profile

(Get Rating)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

See Also

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.